All In Biotech

Drug Trial Radar · NCT05603039

A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma

A Phase Ib/II Trial to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of QL1706 or QL1604 Combined With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

80

Planned (sponsor's estimate)

Start

Jul 1, 2021

Primary completion

Dec 30, 2023

Study completion Dec 30, 2023

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase Ib/II trial to evaluate the safety, pharmacokinetics and preliminary efficacy of QL1706 or QL1604 combined with bevacizumab in patients with advanced hepatocellular carcinoma.

Conditions

  • Advanced Liver Cancer

Interventions

  • QL1706Drug

    5 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV

  • QL1604Drug

    200mg#D1#Q3W IV

  • BevacizumabDrug

    15 mg/kg#D1#Q3W IV or 7.5 mg/kg#D1#Q3W IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective remission rate (ORR)Time frame: up to 1year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.